Dziadziuszko, R, Krebs, M G, de Braud, F, Siena, S, Drilon, A, Doebele, R C, Patel, M R, Chul Cho, B, Liu, S V, Ahn, M J, Chiu, C H, Farago, A F, Lin, C C, Karapetis, C S, Li, Y C, Day, B M, Chen, D, Wilson, T R & Barlesi, F 2021, ' Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer ', Journal of Clinical Oncology, vol. 39, no. 11, pp. 1253-1263 . https://doi.org/10.1200/JCO.20.03025
Lancet Oncology Lancet Oncology, 2020, 21 (2), pp.261-270. ⟨10.1016/S1470-2045(19)30690-4⟩ The Lancet Oncology The Lancet Oncology, 2020, 21 (2), pp.261-270. ⟨10.1016/S1470-2045(19)30690-4⟩ Drilon, A, Siena, S, Dziadziuszko, R, Barlesi, F, Krebs, M G, Shaw, A T, De Braud, F, Rolfo, C, Ahn, M, Wolf, J, Seto, T, Cho, B C, Patel, M R, Chiu, C, John, T, Goto, K, Karapetis, C S, Arkenau, H, Kim, S, Ohe, Y, Li, Y, Chae, Y K, Chung, C H, Otterson, G A, Murakami, H, Lin, C, Tan, D S W, Prenen, H, Riehl, T, Chow-maneval, E, Simmons, B, Cui, N, Johnson, A, Eng, S, Wilson, T R & Doebele, R C 2019, ' Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials ', The Lancet Oncology, vol. 21, no. 2, pp. 261-270 . https://doi.org/10.1016/S1470-2045(19)30690-4 The lancet oncology